NHIS data show the share of US children aged 5 to 17 years ever diagnosed with ADHD climbed from 9.9% in 2019 to 13.8% in 2025.

Lower maternal PlGF in the third trimester was tied to child ADHD in a University of Iowa cohort, independent of preeclampsia and FGR.

Self-harm risk in ADHD peaked in the 90 days before medication initiation and declined once treatment began, a 5-system analysis found.

In PROGRESS Cohort 2, zilurgisertib reduced total HO volume vs placebo at 24 weeks in children aged 6 to 11 with FOP, with no new HO lesions.

Registry data presented at ASN Kidney Week 2026 linked SCD-PED to higher 90-day survival vs historical controls in pediatric sepsis-associated AKI.

The FDA approved insulin icodec-abae for children 10+ with T2D, based on adult ONWARDS data and a single-dose pediatric pharmacokinetic study.

FDA approves berotralstat 150-mg oral pellets for HAE prophylaxis in patients 12+ who cannot or prefer not to swallow capsules.

Tezepelumab produced histologic remission in up to 68.9% of patients aged 12+ with EoE vs 3.5% with placebo at week 24, sustained to week 52.